Diabetes &
Primary Care

Issue:

Share this article

+ Add to reading list - Remove from my list

At a glance factsheet: GLP-1 receptor agonists and diabetic retinopathy

Stephen Bain

An unexpected safety signal emerged from the SUSTAIN 6 cardiovascular outcomes trial of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) semaglutide, whereby increased rates of diabetic retinopathy were observed in trial participants randomised to semaglutide. This finding has, justifiably, led to a great deal of investigation and caution. This At a Glance factsheet outlines the evidence regarding diabetic retinopathy in users of the GLP-1 RA class as a whole, and provides recommendations on safe use.

Save, Share, Print Article

Share this article

+ Add to reading list – Remove from reading list

↓ Download pdf

Readers are directed to the PDF version of this article.

At a glance factsheet, Microvascular complications, Newer therapies, Retinopathy

Diabetes &
Primary Care

At a glance factsheet: GLP-1 receptor agonists and diabetic retinopathy

Conference over coffee: New medicines, goals of triple therapy, AI prescribing, hypoglycaemia and lipids

Diabetes Distilled: Cardiovascular autonomic neuropathy – prevention, identification and management

Interactive case study: Managing acute illness in type 2 diabetes

Diabetes Distilled: ABCD–UKKA concise recommendations for management of CKD in type 2 diabetes

Welcome to the new PCDS Chair and Secretary

Conference over coffee: Diabetes and obesity initiatives, multiple long-term condition management and the bookends of pregnancy

Scottish Government and NHS Scotland consensus statement on GLP-1-based therapies for obesity